NASDAQ Healthcare Biotechnology BIOA

BioAge Labs, Inc.

$ 20.77 3.90 %

BioAge Labs, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing therapeutic solutions for metabolic illnesses. The company employs a distinctive technology platform alongside specialized human datasets to pinpoint potential drug targets by unraveling the molecular mechanisms underlying the aging process. Their current pipeline features azelaprag, an oral small molecule, which is undergoing Phase 1 clinical trials for obesity. Additionally, BioAge has commenced a Phase 2 clinical trial for azelaprag, investigating its efficacy in combination with tirzepatide for managing obesity specifically in older adults. Another asset under development is BGE-100, an oral, brain-penetrant small molecule designed to act as an NLRP3 antagonist, aiming to address conditions characterized by neuroinflammation. Established in 2015, BioAge Labs, Inc. operates from its headquarters in Richmond, California.

CEO: Kristen Fortney - https://bioagelabs.com

Summary 30-Y Financials Dividend Analyst Key metrics Ownership / Senat
Price objectif

$42.2 103.18 %

Recommandation

Buy

DCF

$ 9.19

Loading data...

BIOA vs S&P500

Loading data...

No data available.

Quick ratio

24.76

suggests a healthy liquidity position, showing that the company can likely meet its short-term obligations.

P/E ratio

-8.65

may indicate that the company is undervalued or has poor growth prospects.

EPS

-2.40

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

-29.40 %

indicates low profitability, suggesting that the company is not using equity efficiently to generate profits.

ROIC

-26.51 %

does not generate enough return to cover its financing costs, which indicates value destruction and may pose long-term profitability issues.

WACC

8.72

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

0.01

indicates that the company uses more equity than debt, suggesting prudent management.

Free cash flow per share

-2.09

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

0.00 %

the dividend payout ratio is the measure of dividends paid out to shareholders relative to the company's net income.

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
3 indicates worrying financial health
Altman score
24.48 indicates good financial health and low risk of bankruptcy
Loading data...

No data available.

Cash / Debt

Cash Ratio
15.28 indicates that the company has sufficient cash to cover its short-term debts
Debt Ratio
0.01 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.